Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

British Journal of Cancer

Volumn 111, Issue 11, 2014, Pages 2051-2057

  Brodowicz, T ^a   Lang, I ^b   Kahan, Z ^c   Greil, R ^d   Beslija, S ^e   Stemmer, S M ^f   Kaufman, B ^g   Petruzelka, L ^h   Eniu, A ⁱ   Anghel, R ^j   Koynov, K ^k   Vrbanec, D ^l   Pienkowski, T ^m   Melichar, B ⁿ   Spanik, S ^o   Ahlers, S ^p   Messinger, D ^p   Inbar, M J ^q   Zielinski, C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d PARACELSUS MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^f RABIN MEDICAL CENTER   (Israel)

^g SHEBA MEDICAL CENTER   (Israel)

^h CHARLES UNIVERSITY   (Czech Republic)

ⁱ Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^j CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^k Serdika Hospital   (Bulgaria)

^l KBC Zagreb   (Croatia)

^m Oncology Department   (Poland)

ⁿ PALACKÝ UNIVERSITY   (Czech Republic)

^o St Elisabeth Cancer Institute   (Slovakia)

^p IST GmbH   (Germany)

^q TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

more..

Author keywords

bevacizumab; metastatic breast cancer; risk factor prognostic index; triple negative breast cancer

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; PACLITAXEL; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BONE PAIN; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; DEEP VEIN THROMBOSIS; DISEASE FREE INTERVAL; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; EPILEPSY; EPISTAXIS; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOCALCEMIA; LEUKOPENIA; LIMB PAIN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MYALGIA; NAIL DISEASE; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PATIENT HISTORY OF CHEMOTHERAPY; PATIENT PREFERENCE; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; POLYNEUROPATHY; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; SENSORY NEUROPATHY; SPEECH DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; TRIPLE NEGATIVE BREAST CANCER; VISCERAL METASTASIS; VOMITING; ADULT; AGED; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RISK FACTORS;

EID: 84927178550     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.504     Document Type: Article

References (17)

1. Baselga J, Gomez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pego A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melez?nkova H, Awada A (2013) Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 31: 2586-2592.
2. Brufsky A, Valero V, Tiangco B, Dakhil S, Brize A, Rugo HS, Rivera R, Duenne A, Bousfoul N, Yardley DA (2012) Second-line bevacizumabcontaining therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 133: 1067-1075.
3. Dawood S, Shaikh AJ, Buchholz TA, Cortes J, Cristofanilli M, Gupta S, Gonzalez-Angulo AM (2012) The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy. Cancer 118: 2780-2786.
4. Inbar MJ, Lang I, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Ahlers S, Brodowicz T, Zielinski C. Central European Cooperative Oncology Group (2013) Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): subgroup analysis of TURANDOT. J Clin Oncol 31(suppl): abstract 1040.
5. Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C. Central European Cooperative Oncology Group (2013) Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol 14: 125-133.
6. Lang I, Inbar MJ, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Ahlers S, Brodowicz T, Zielinski C (2012) Quality of life results from the TURANDOT trial comparing two bevacizumab-containing regimens as first-line treatment for HER2-negative metastatic breast cancer. Cancer Res 72(24 suppl): 462s (poster P5-17-03).
7. Llombart-Cussac A, Pivot XB, Biganzoli L, Cortes-Funes H, Pritchard KI, Pierga J-Y, Smith IE, Thomssen C, Palacios G, Srock S, Sampayo M, Cortes J (2013) A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: analysis from the ATHENA trial. J Clin Oncol 31(suppl): abstract 555.
8. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28: 3239-3247.
9. Miles D, Dieras V, Cortes JA, Duenne AA, Yi J, O'Shaughnessy J (2013) First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 24: 2773-2780.
10. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676.
11. O'Shaughnessy J, Dieras V, Glaspy J, Brufsky A, Miller K, Miles D, Koralewski D, Phan S, Bhattacharya S (2009) Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC). Cancer Res 69(suppl): 512s (abstract 207).
12. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C (2011a) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364: 205-214.
13. O'Shaughnessy J, Schwartzberg LS, Danso MA, Rugo HS, Miller K, Yardley DA, Carlson RW, Finn RS, Charpentier E, Freese M, Gupta S, Blackwood-Chirchir A, Winer EP (2011b) A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 29(suppl): abstract 1007.
14. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 29: 1252-1260.
15. Roche data on file (2007) A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab (rhuMAb VEGF) as first-line therapy for locally recurrent or metastatic breast cancer. Clinical Study Report E2100.
16. Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Mayer EL, Naughton M, Layman RM, Carey LA, Somer RA, Perez EA, Hudis C, Winer EP (2012) CALGB 40502/NCCTG N063H: randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 30(suppl): abstract CRA1002.
17. von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Muller BM, Denkert C, Loibl S, Nekljudova V, Untch M. German Breast Group; Arbeitsgemeinschaft Gynakologische Onkologie-Breast Study Groups (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366: 299-309.